COSTA MESA, Calif./IReach–PRNewswire/–WCCT Global™ an international specialized clinical research organization, today introduced Bill Taaffe as its new Chief Executive Officer.
Mr. Taaffe has served on WCCT’s Board of Directors since 2012 and has also served as President of Medelis, a specialty oncology CRO which merged with WCCT in May of 2016. Prior to joining WCCT’s Board of Directors, Mr. Taaffe was one of the founding members of ICON plc. He joined ICON’s U.S. clinical operations in 1993 and oversaw its growth from nine employees to over 4,500 employees, achieving 12 consecutive years of growth and regional expansion. Mr. Taaffe also served as ICON’s President of Corporate Development and President of DOCS, ICON’s staffing division.
“I am excited to take on this new role at WCCT Global, a company I have seen grow immensely over the past few years,” said Mr. Taaffe. “I am confident that the company will continue to expand and build upon the great foundation which has been established by Dr. Kenneth Kim since its founding in 1998.”
WCCT Global began as an independent research clinic focused on patients with asthma and various allergies and has grown into a multi-site, multi-therapeutic clinical research organization with specializations in conducting Phase I, Ethnic Sensitivity, Viral Challenge, orphan disease, and special patient population studies. The Medelis merger in 2016 expanded its reach into Phase II through Phase IV oncology studies.
WCCT Global founder and former CEO, Dr. Kenneth Kim, will continue to serve the organization as its new Chief Medical Officer and remain on the Board of Directors. “I am happy to see that this organization has grown into something far beyond what I could have imagined in its earliest days,” said Dr. Kim. “Words cannot express how grateful I am to have been able to serve this company for so long and so successfully. I am confident in Bill Taaffe’s leadership as we continue to expand our global presence and service offerings.”